<DOC>
	<DOCNO>NCT00251459</DOCNO>
	<brief_summary>This Phase IIIb , single-masked , 1-year multicenter study safety tolerability intravitreally administer ranibizumab subject active subfoveal CNV secondary AMD .</brief_summary>
	<brief_title>A Study Evaluate Ranibizumab Subjects With Choroidal Neovascularization ( CNV ) Secondary Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥ 50 year Subfoveal CNV secondary AMD , evidence recent disease progression , define follow ( lesion eligible meet one follow criterion ) : ≥ 5 letter ( ≥ 1 Snellen line ) BCVA lose within 6 month precede Day 0\ ; ≥ 10 % increase lesion area , determine compare FA perform within 1 month precede Day 0 FA perform within 6 month precede Day 0 ; Subretinal hemorrhage associate CNV within 1 month precede Day 0 ; Classic CNV comprise &gt; 50 % CNV lesion area BCVA , use ETDRS chart Cohort 1 Snellen chart Cohort 2 , 20/40 20/320 ( Snellen equivalent ) study eye Treatment verteporfin PDT , pegaptanib sodium , AMD therapy study eye &lt; 30 day precede Day 0 History submacular surgery surgical intervention AMD study eye Previous participation study investigational drug within 30 day precede Day 0 ( exclude vitamin mineral ) Prior participation Genentech ranibizumab clinical trial Treatment intravitreally administer ( either eye ) Avastin ( R ) ( bevacizumab ) within 30 day precede Day 0 Concurrent use systemic antiVEGF agent Fibrosis atrophy involve center fovea study eye , absence new lesion CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Retinal pigment epithelial tear involve macula study eye Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either require medical surgical intervention 12month study period prevent treat visual loss might result condition , , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line BCVA 12month study period Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia pseudophakia absence posterior capsule ( unless occur result yttrium aluminum garnet [ YAG ] posterior capsulotomy ) Spherical equivalent refractive error study eye demonstrate 8 diopter myopia Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Day 0 Uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma medication ) Concurrent use one therapy glaucoma History glaucoma filter surgery study eye History corneal transplant study eye Premenopausal woman use adequate contraception Pregnancy lactation History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current treatment significant active systemic infection Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder History recurrent significant infection bacterial infection Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>SAILOR</keyword>
	<keyword>CNV</keyword>
	<keyword>AMD</keyword>
	<keyword>CNV secondary AMD</keyword>
</DOC>